A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

May 31 (Reuters) - Johnson & Johnson's (JNJ.N) ​prostate cancer drug Erleada used with hormone-blocking therapy six months ...

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy ...

Former first lady Jill Biden opened up about her husband’s battle with prostate cancer in a new interview. She said in a ...

High-end longevity clinics are springing up from Singapore to Southern California. They aim to prevent diseases.

Researchers tested opaganib in combination with standard hormone therapies in men with resistant prostate cancer. They ...

A study shows that detecting tumor DNA in blood can reveal prostate cancer treatment failure weeks earlier than PSA tests, ...

For more than a decade, millions of men heard the same message from their doctors: a routine PSA blood test probably was not worth the trouble. Major guidelines warned that the prostate-specific ...

Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment Screening for prostate cancer with a blood test can save men’s lives, but the “absolute ...

Knowable Magazine reports that many cancer survivors, like Kara Kenan, face ongoing health challenges post-treatment, but ...